NCT02323685View on ClinicalTrials.gov

Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

October 31, 2016

Conditions
Cerebral Ischemia
Interventions
BIOLOGICAL

SANGUINATE™

Single infusion of SANGUINATE (pegylated carboxyhemogloblin)

Trial Locations (1)

63110

Barnes Jewish Hospital/Washington University, St Louis

Sponsors
All Listed Sponsors
lead

Prolong Pharmaceuticals

INDUSTRY